311 related articles for article (PubMed ID: 24166007)
1. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.
Friedlander TW; Ngo VT; Dong H; Premasekharan G; Weinberg V; Doty S; Zhao Q; Gilbert EG; Ryan CJ; Chen WT; Paris PL
Int J Cancer; 2014 May; 134(10):2284-93. PubMed ID: 24166007
[TBL] [Abstract][Full Text] [Related]
2. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer.
Premasekharan G; Gilbert E; Okimoto RA; Hamirani A; Lindquist KJ; Ngo VT; Roy R; Hough J; Edwards M; Paz R; Foye A; Sood R; Copren KA; Gubens M; Small EJ; Bivona TG; Collisson EA; Friedlander TW; Paris PL
Cancer Lett; 2016 Sep; 380(1):144-52. PubMed ID: 27343980
[TBL] [Abstract][Full Text] [Related]
3. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
[TBL] [Abstract][Full Text] [Related]
4. Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916908
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
Paller CJ; Piana D; Eshleman JR; Riel S; Denmeade SR; Isaacsson Velho P; Rowe SP; Pomper MG; Antonarakis ES; Luo J; Eisenberger MA
Prostate; 2019 Oct; 79(14):1597-1603. PubMed ID: 31361358
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
[TBL] [Abstract][Full Text] [Related]
7. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.
Nagaya N; Nagata M; Lu Y; Kanayama M; Hou Q; Hotta ZU; China T; Kitamura K; Matsushita K; Isotani S; Muto S; Sakamoto Y; Horie S
PLoS One; 2020; 15(1):e0226219. PubMed ID: 31986176
[TBL] [Abstract][Full Text] [Related]
9. Vita-Assay™ Method of Enrichment and Identification of Circulating Cancer Cells/Circulating Tumor Cells (CTCs).
Tulley S; Zhao Q; Dong H; Pearl ML; Chen WT
Methods Mol Biol; 2016; 1406():107-19. PubMed ID: 26820949
[TBL] [Abstract][Full Text] [Related]
10. Impact of Circulating Tumor Cell-Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer.
Cho H; Byun SS; Son NH; Chung JI; Seo WI; Lee CH; Morgan TM; Han KH; Chung JS
Clin Cancer Res; 2024 May; 30(9):1788-1800. PubMed ID: 38587547
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
McDaniel AS; Ferraldeschi R; Krupa R; Landers M; Graf R; Louw J; Jendrisak A; Bales N; Marrinucci D; Zafeiriou Z; Flohr P; Sideris S; Crespo M; Figueiredo I; Mateo J; de Bono JS; Dittamore R; Tomlins SA; Attard G
BJU Int; 2017 Nov; 120(5B):E30-E44. PubMed ID: 27539393
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
Scher HI; Armstrong AJ; Schonhoft JD; Gill A; Zhao JL; Barnett E; Carbone E; Lu J; Antonarakis ES; Luo J; Tagawa S; Dos Anjos CH; Yang Q; George D; Szmulewitz R; Danila DC; Wenstrup R; Gonen M; Halabi S
Eur J Cancer; 2021 Jun; 150():83-94. PubMed ID: 33894633
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.
Lustberg MB; Balasubramanian P; Miller B; Garcia-Villa A; Deighan C; Wu Y; Carothers S; Berger M; Ramaswamy B; Macrae ER; Wesolowski R; Layman RM; Mrozek E; Pan X; Summers TA; Shapiro CL; Chalmers JJ
Breast Cancer Res; 2014 Mar; 16(2):R23. PubMed ID: 24602188
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.
Massard C; Oulhen M; Le Moulec S; Auger N; Foulon S; Abou-Lovergne A; Billiot F; Valent A; Marty V; Loriot Y; Fizazi K; Vielh P; Farace F
Oncotarget; 2016 Aug; 7(34):55069-55082. PubMed ID: 27391263
[TBL] [Abstract][Full Text] [Related]
15. Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer.
Pearl ML; Zhao Q; Yang J; Dong H; Tulley S; Zhang Q; Golightly M; Zucker S; Chen WT
Gynecol Oncol; 2014 Sep; 134(3):581-90. PubMed ID: 24972191
[TBL] [Abstract][Full Text] [Related]
16. Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs).
Pearl ML; Dong H; Tulley S; Zhao Q; Golightly M; Zucker S; Chen WT
Gynecol Oncol; 2015 May; 137(2):229-38. PubMed ID: 25769657
[TBL] [Abstract][Full Text] [Related]
17. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response.
Satelli A; Brownlee Z; Mitra A; Meng QH; Li S
Clin Chem; 2015 Jan; 61(1):259-66. PubMed ID: 25336717
[TBL] [Abstract][Full Text] [Related]
19. Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System.
Xu L; Mao X; Imrali A; Syed F; Mutsvangwa K; Berney D; Cathcart P; Hines J; Shamash J; Lu YJ
PLoS One; 2015; 10(9):e0138032. PubMed ID: 26397728
[TBL] [Abstract][Full Text] [Related]
20. Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients.
Danila DC; Samoila A; Patel C; Schreiber N; Herkal A; Anand A; Bastos D; Heller G; Fleisher M; Scher HI
Cancer J; 2016; 22(5):315-320. PubMed ID: 27749322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
